Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

145 - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.


24 Nov 2018


Poster display - Cocktail


Pathology/Molecular Biology

Tumour Site

Breast Cancer


Abhishek Anand


Annals of Oncology (2018) 29 (suppl_9): ix13-ix20. 10.1093/annonc/mdy428


A. Anand1, L.A. Jacob1, K.C. Lakshmaiah1, K. Govind Babu1, D. Lokanatha1, M.C. Suresh Babu1, K..N. Lokesh1, A.H. Rudresha1, L.K. Rajeev1, S.C. Saldanha1, G. Giri1, R. Patidar1, V. Asati1, R. Chethan1, T. Chaudhuri1, D. Koppaka1, D. Panwar2, R.V. Kumar2

Author affiliations

  • 1 Medical Oncology, Kidwai Cancer Institute, 560029 - Bengaluru/IN
  • 2 Pathology, Kidwai Cancer Institute, 560029 - Bangalore/IN


Abstract 145


Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are therapeutically as well as prognostically important. The discordance of ER, PR, and HER2 between primary and the recurrent breast cancer has been recognized in studies with few reporting change in therapy as well. However, many still use report of primary tumor to guide treatment in the recurrent setting and FNA is a routine to label a lesion metastasis without knowing the IHC before starting further treatment.


This was an observational study carried out from September 2015 to February 2017. All recurrent (locoregional or metastatic) breast cancer patients were analyzed. Biopsy was done from the recurrent site and IHC study was performed. The discordance of ER, PR and HER2 status between primary tumor and recurrent disease were analyzed. Mc Nemar test on SPSS version 23.0 was used to see the statistical significance.


A total of 78 patients were analyzed. Thirty five (45%) patients had only locoregional, 14 (18%) had only visceral and 29 (37%) had locoregional alongwith visceral metastasis at recurrence. The discordance rate for ER was 13.7% (n = 11; p=.227). Among these, 3 (3.7%) had ER changed from positive to negative whereas 8 (10%) had change from negative to positive. The discordance rate for PR was higher with 28.7% (n = 23; p=.017). Those who had receptor changed from positive to negative was 6 (7.5%) while 17 (21.2%) had change from negative to positive. The discordance of HER2 was seen in 21.2% (n = 17; p=.013) with 3 (3.7%) showing change from positive to negative and 14 (17.5%) from negative to positive. Overall, a higher number of patients had receptor negative in primary to receptor positive in the recurrent specimen than converting from positive to negative This led to a newer treatment option in 31% of patients.


Routine biopsy and analyses for ER, PR, and HER2 status in the recurrent setting should be done in all patients, which have important implications in the management as well as prognosis.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Kidwai Cancer Institute, Bangalore.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.